Recommendations by the Tuscan Health Authority to Use Infliximab-Biosimilar in the Clinical Practice: Safety Impact

Irma Convertino; Ersilia Lucenteforte; Lorenzoni; Giuseppe Turchetti; Leopoldo Trieste; Giuseppe Roberto; Massimiliano Cazzato; Marta Mosca; Sara Ferraro; Luca Leonardi

doi:10.1007/s40264-019-00855-w

Recommendations by the Tuscan Health Authority to Use Infliximab-Biosimilar in the Clinical Practice: Safety Impact

Identifier:nobleid.org/w1/20260515/CEF2FC6D

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/CEF2FC6D.svg?ark=w1%2F20260515%2FCEF2FC6D)](https://nobleid.org/work/w1/20260515/CEF2FC6D)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Recommendations by the Tuscan Health Authority to Use Infliximab-Biosimilar in the Clinical Practice: Safety Impact

Identifier:nobleid.org/w1/20260515/CEF2FC6D

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/CEF2FC6D.svg?ark=w1%2F20260515%2FCEF2FC6D)](https://nobleid.org/work/w1/20260515/CEF2FC6D)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work